Compare Gilead Sciences, Inc. (GILD) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs M&T Bank Corporation — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while M&T Bank Corporation trades at $217.49 (market cap $31.42B). The key difference: Gilead Sciences, Inc. is far larger — about 5.8× M&T Bank Corporation's market cap, and M&T Bank Corporation pays the higher dividend (2.76%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and M&T Bank Corporation for 100 Days on average.
| GILD | MTB | |
|---|---|---|
Market Cap | $182.40B | $31.42B |
Volume | 4,469,821 | 1,438,219 |
Sector | Health | Financials |
52-Week High | $155.80 | $254.09 |
52-Week Low | $116.74 | $178.63 |
Typical Hold Time | 111 Days | 100 Days |
Enterprise Value | $205.46B | $47.77B |
Dividend Yield | 2.23% | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
MTB trades at $217.49, up 0.41% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with a P/E of 11.52, net income margin of 30.85%, and three consecutive quarterly EPS beats. Recent news highlights loan growth, AI investments, and a new branch opening, while the company maintains a consistent dividend.
The outlook is mixed; analyst consensus is a Buy with a $258.92 price target, but technicals suggest near-term pressure. Key opportunities include earnings momentum and dividend stability, while risks involve cash flow volatility and high debt levels. The stock offers value but requires monitoring of upcoming Q3 2026 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
